Amgen Given Average Recommendation of “Buy” by Brokerages (NASDAQ:AMGN)
Amgen (NASDAQ:AMGN) has been given an average recommendation of “Buy” by the twenty brokerages that are covering the company, AnalystRatings.Net reports. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $139.44.
Shares of Amgen (NASDAQ:AMGN) opened at 126.95 on Tuesday. Amgen has a 1-year low of $103.88 and a 1-year high of $131.24. The stock’s 50-day moving average is $121.5 and its 200-day moving average is $119.3. The company has a market cap of $96.432 billion and a price-to-earnings ratio of 19.25.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.07 by $0.30. The company had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter in the previous year, the company posted $1.89 earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. Analysts expect that Amgen will post $8.37 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Thursday, August 14th will be given a dividend of $0.61 per share. This represents a $2.44 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend is Tuesday, August 12th.
In other Amgen news, EVP Sean E. Harper sold 14,000 shares of the company’s stock on the open market in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $127.29, for a total value of $1,782,060.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on AMGN shares. Analysts at Argus reiterated a “buy” rating on shares of Amgen in a research note on Monday, August 4th. They now have a $140.00 price target on the stock, up previously from $135.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Amgen in a research note on Thursday, July 31st. They now have a $137.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Amgen from $135.00 to $140.00 in a research note on Thursday, July 31st.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.